Pharmaceutical firm Jubilant Organosys today said it has entered into an agreement with the US-based BioLeap for drug discovery.
Under the agreement, BioLeap's computational fragment based drug design platform would be integrated with Jubilant's expertise in other different areas to offer a highly competitive preclinical drug development platform, Jubilant Organosys said in a filing to the Bombay Stock Exchange.
"The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimisation to Investigational New Drug candidate selection for multiple therapeutic areas," the company said.
"We are delighted to have the opportunity to offer our partners the combined capabilities of Jubilant and BioLeap," BioLeap Chief Business Officer Gerald Evans said.